

Kasia J Lipska

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2561557/publications.pdf>

Version: 2024-02-01

98
papers

4,901
citations

147801
31
h-index

98798
67
g-index

103
all docs

103
docs citations

103
times ranked

6107
citing authors

#	ARTICLE	IF	CITATIONS
1	Diabetes and the WHO Model List of Essential Medicines. Lancet Diabetes and Endocrinology, 2022, 10, 17-18.	11.4	1
2	Rates of, and factors associated with, switching among generic levothyroxine preparations in commercially insured American adults. Endocrine, 2022, 76, 349-358.	2.3	2
3	Defining Minimum Necessary Communication During Care Transitions for Patients on Antihyperglycemic Medication: Consensus of the Care Transitions Task Force of the IPRO Hypoglycemia Coalition. Diabetes Therapy, 2022, 13, 535-549.	2.5	0
4	Glucagon-Like Peptide-1 Receptor Agonists—How Safe Are They?. JAMA Internal Medicine, 2022, 182, 520.	5.1	2
5	Fingerstick Glucose Monitoring in Veterans Affairs Nursing Home Residents with Diabetes Mellitus. Journal of the American Geriatrics Society, 2021, 69, 424-431.	2.6	4
6	Newly diagnosed diabetes and outcomes after acute myocardial infarction in young adults. Heart, 2021, 107, 657-666.	2.9	8
7	Estimates of insulin needs and dispensation given wastage, alternative glycemic targets, and non-insulin therapies in US populations with type 2 diabetes mellitus: A microsimulation study. Journal of Diabetes and Its Complications, 2021, 35, 107839.	2.3	4
8	Glucagon use by U.S. adults with type 1 and type 2 diabetes. Journal of Diabetes and Its Complications, 2021, 35, 107882.	2.3	16
9	The Cost and Safety of Insulin in Older Adults. JAMA Internal Medicine, 2021, 181, 608.	5.1	1
10	Qualitative analysis of reasons for hospitalization for severe hypoglycemia among older adults with diabetes. BMC Geriatrics, 2021, 21, 318.	2.7	3
11	Beyond hemoglobin A1c: a videographic analysis of conversations about quality of life and treatment burden during clinical encounters for diabetes care. Endocrine, 2021, 73, 573-579.	2.3	3
12	Levothyroxine Use in the United States, 2008-2018. JAMA Internal Medicine, 2021, 181, 1402.	5.1	42
13	Cardiovascular outcomes and rates of fractures and falls among patients with brand-name versus generic L-thyroxine use. Endocrine, 2021, 74, 592-602.	2.3	2
14	Contemporary National Patterns of Eligibility and Use of Novel Cardioprotective Antihyperglycemic Agents in Type 2 Diabetes Mellitus. Journal of the American Heart Association, 2021, 10, e21084.	3.7	35
15	Quality of life, burden of treatment, safety, and avoidance of future events (QBSafe) protocol: a pilot study testing an intervention to shift the paradigm of diabetes care. Pilot and Feasibility Studies, 2021, 7, 196.	1.2	2
16	Patterns of Prescribing Sodium-Glucose Cotransporter-2 Inhibitors for Medicare Beneficiaries in the United States. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, .	2.2	27
17	Documentation of hypoglycemia assessment among adults with diabetes during clinical encounters in primary care and endocrinology practices. Endocrine, 2020, 67, 552-560.	2.3	6
18	Comparative Effectiveness of Generic vs Brand-Name Levothyroxine in Achieving Normal Thyrotropin Levels. JAMA Network Open, 2020, 3, e2017645.	5.9	18

#	ARTICLE	IF	CITATIONS
19	Self-care practices and needs in patients with hypertension, diabetes, or both in rural Uganda: a mixed-methods study. <i>The Lancet Global Health</i> , 2020, 8, S19.	6.3	4
20	Development and evaluation of a patient-centered quality indicator for the appropriateness of type 2 diabetes management. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001878.	2.8	4
21	Changes in Management of Type 2 Diabetes Before and After Severe Hypoglycemia. <i>Diabetes Care</i> , 2020, 43, e188-e189.	8.6	6
22	Expensive Insulin—The Epicenter of a Large, Life-Threatening Problem. <i>JAMA Internal Medicine</i> , 2020, 180, 931.	5.1	5
23	Development of a discrete choice experiment to understand patient preferences for diabetes and hypertension management in rural Uganda. <i>The Lancet Global Health</i> , 2020, 8, S22.	6.3	6
24	Association of Cumulative Multimorbidity, Glycemic Control, and Medication Use With Hypoglycemia-Related Emergency Department Visits and Hospitalizations Among Adults With Diabetes. <i>JAMA Network Open</i> , 2020, 3, e1919099.	5.9	65
25	Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2020, 141, e779-e806.	1.6	157
26	Paradox of glycemic management: multimorbidity, glycemic control, and high-risk medication use among adults with diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001007.	2.8	29
27	Racial and Ethnic Differences in 30-Day Hospital Readmissions Among US Adults With Diabetes. <i>JAMA Network Open</i> , 2019, 2, e1913249.	5.9	38
28	Association of Diabetes Mellitus With Health Status Outcomes in Young Women and Men After Acute Myocardial Infarction: Results From the VIRGO Study. <i>Journal of the American Heart Association</i> , 2019, 8, e010988.	3.7	15
29	Metformin for Type 2 Diabetes—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1313.	7.4	2
30	Use and Discontinuation of Insulin Treatment Among Adults Aged 75 to 79 Years With Type 2 Diabetes. <i>JAMA Internal Medicine</i> , 2019, 179, 1633.	5.1	28
31	Insulin Analogues for Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 350.	7.4	13
32	Lack of Glycemic Legacy Effects in the Veterans Affairs Diabetes Trial. <i>New England Journal of Medicine</i> , 2019, 380, 2266-2267.	27.0	6
33	Generic and Brand-Name Thyroid Hormone Drug Use Among Commercially Insured and Medicare Beneficiaries, 2007 Through 2016. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2305-2314.	3.6	24
34	Metformin in 2019. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1926.	7.4	270
35	Revalidation of the Hypoglycemia Risk Stratification Tool Using ICD-10 Codes. <i>Diabetes Care</i> , 2019, 42, e58-e59.	8.6	17
36	Estimation of global insulin use for type 2 diabetes, 2018–30: a microsimulation analysis. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 25-33.	11.4	138

#	ARTICLE	IF	CITATIONS
37	Admission diagnoses among patients with heart failure: Variation by ACO performance on a measure of risk-standardized acute admission rates. <i>American Heart Journal</i> , 2019, 207, 19-26.	2.7	0
38	Cost-Related Insulin Underuse Among Patients With Diabetes. <i>JAMA Internal Medicine</i> , 2019, 179, 112.	5.1	156
39	Surveillance of Hypoglycemia—Limitations of Emergency Department and Hospital Utilization Data. <i>JAMA Internal Medicine</i> , 2018, 178, 987.	5.1	52
40	Use of Intensive Glycemic Management in Older Adults with Diabetes Mellitus. <i>Journal of the American Geriatrics Society</i> , 2018, 66, 1190-1194.	2.6	53
41	Defining Multiple Chronic Conditions for Quality Measurement. <i>Medical Care</i> , 2018, 56, 193-201.	2.4	14
42	Recurrent hospitalizations for severe hypoglycemia and hyperglycemia among U.S. adults with diabetes. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 693-701.	2.3	25
43	Diabetes, Heart Disease, and Dementia: National Estimates of Functional Disability Trajectories. <i>Journal of the American Geriatrics Society</i> , 2018, 66, 766-772.	2.6	10
44	Association of Initiation of Basal Insulin Analogs vs Neutral Protamine Hagedorn Insulin With Hypoglycemia-Related Emergency Department Visits or Hospital Admissions and With Glycemic Control in Patients With Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 53.	7.4	64
45	Availability and Affordability of Essential Medicines: Implications for Global Diabetes Treatment. <i>Current Diabetes Reports</i> , 2018, 18, 48.	4.2	30
46	Is the Over-the-Counter Availability of Human Insulin in the United States Good or Bad?. <i>JAMA Internal Medicine</i> , 2018, 178, 1157.	5.1	5
47	Effects of Physical Activity Intervention on Physical and Cognitive Function in Sedentary Adults With and Without Diabetes. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2017, 72, glw179.	3.6	47
48	Is Hemoglobin A _{1c} the Right Outcome for Studies of Diabetes?. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1017.	7.4	76
49	Strategies to improve the affordability of insulin in the USA. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 158-159.	11.4	33
50	Human Insulin for Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 23.	7.4	67
51	High rates of severe hypoglycemia among African American patients with diabetes: the surveillance, prevention, and Management of Diabetes Mellitus (SUPREME-DM) network. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 869-873.	2.3	44
52	Metformin Use in Patients With Historical Contraindications. <i>Annals of Internal Medicine</i> , 2017, 166, 225.	3.9	7
53	Development and Validation of a Tool to Identify Patients With Type 2 Diabetes at High Risk of Hypoglycemia-Related Emergency Department or Hospital Use. <i>JAMA Internal Medicine</i> , 2017, 177, 1461.	5.1	105
54	Hypoglycemia Patients and Transport by EMS in Alameda County, 2013–15. <i>Prehospital Emergency Care</i> , 2017, 21, 767-772.	1.8	22

#	ARTICLE	IF	CITATIONS
55	Hemoglobin A1c as a Surrogate for Clinical Outcomes in Diabetes Studies”Reply. JAMA - Journal of the American Medical Association, 2017, 318, 200.	7.4	2
56	Hospital Readmissions among Commercially Insured and Medicare Advantage Beneficiaries with Diabetes and the Impact of Severe Hypoglycemic and Hyperglycemic Events. Journal of General Internal Medicine, 2017, 32, 1097-1105.	2.6	38
57	Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006”2013. Diabetes Care, 2017, 40, 468-475.	8.6	249
58	Risk-standardized Acute Admission Rates Among Patients With Diabetes and Heart Failure as a Measure of Quality of Accountable Care Organizations. Medical Care, 2016, 54, 528-537.	2.4	15
59	The rising cost of diabetes care in the USA. Lancet Diabetes and Endocrinology,the, 2016, 4, 479-480.	11.4	25
60	Inclusion of Hypoglycemia in Clinical Practice Guidelines and Performance Measures in the Care of Patients With Diabetes. JAMA Internal Medicine, 2016, 176, 1714.	5.1	25
61	Diabetes in Older People. JAMA - Journal of the American Medical Association, 2016, 316, 362.	7.4	3
62	Citizen Petition to the US Food and Drug Administration to Change Prescribing Guidelines: The Metformin Experience. Circulation, 2016, 134, 1405-1408.	1.6	27
63	Physicians frequently fail to de-intensify treatment in older patients with diabetes and very low haemoglobin A1c or blood pressure. Evidence-Based Medicine, 2016, 21, 158-158.	0.6	6
64	Intensive Treatment and Severe Hypoglycemia Among Adults With Type 2 Diabetes. JAMA Internal Medicine, 2016, 176, 969.	5.1	115
65	Predicting Adverse Outcomes After Myocardial Infarction Among Patients With Diabetes Mellitus. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 372-379.	2.2	22
66	Intensive Glycemic Control in Type 2 Diabetes Mellitus”A Balancing Act of Latent Benefit and Avoidable Harm. JAMA Internal Medicine, 2016, 176, 300.	5.1	19
67	Hypoglycemia as an indicator of good diabetes care:. BMJ, The, 2016, 352, i1084.	6.0	26
68	Polypharmacy in the Aging Patient. JAMA - Journal of the American Medical Association, 2016, 315, 1034.	7.4	236
69	Global Noncommunicable Disease Research: Opportunities and Challenges. Annals of Internal Medicine, 2015, 163, 712-714.	3.9	13
70	Association between diabetes mellitus and angina after acute myocardial infarction: analysis of the TRIUMPH prospective cohort study. European Journal of Preventive Cardiology, 2015, 22, 779-787.	1.8	15
71	Recognition of Incident Diabetes Mellitus During an Acute Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 260-267.	2.2	16
72	Potential Overtreatment of Diabetes Mellitus in Older Adults With Tight Glycemic Control. JAMA Internal Medicine, 2015, 175, 356.	5.1	317

#	ARTICLE	IF	CITATIONS
73	The Adherence to Medications in Diabetic Patients in Rural Kerala, India. Asia-Pacific Journal of Public Health, 2015, 27, NP513-NP523.	1.0	52
74	The reliability of in-hospital diagnoses of diabetes mellitus in the setting of an acute myocardial infarction. BMJ Open Diabetes Research and Care, 2014, 2, e000046.	2.8	9
75	Age at diagnosis predicts deterioration in glycaemic control among children and adolescents with type 1 diabetes. BMJ Open Diabetes Research and Care, 2014, 2, e000039.	2.8	48
76	Use and Out-of-Pocket Costs of Insulin for Type 2 Diabetes Mellitus From 2000 Through 2010. JAMA - Journal of the American Medical Association, 2014, 311, 2331.	7.4	75
77	Metformin in Patients With Type 2 Diabetes and Kidney Disease. JAMA - Journal of the American Medical Association, 2014, 312, 2668.	7.4	474
78	National Trends in US Hospital Admissions for Hyperglycemia and Hypoglycemia Among Medicare Beneficiaries, 1999 to 2011. JAMA Internal Medicine, 2014, 174, 1116.	5.1	324
79	The 2013 American Association of Clinical Endocrinologistsâ€™ Diabetes Mellitus Management Recommendations. JAMA Internal Medicine, 2014, 174, 179.	5.1	15
80	Comparing Diabetes Medications. JAMA Internal Medicine, 2014, 174, 317.	5.1	8
81	Improving Safety of Diabetes Mellitus Management. JAMA Internal Medicine, 2014, 174, 1612.	5.1	4
82	AACE Response to Viewpoint of December 9, 2013â€™Reply. JAMA Internal Medicine, 2014, 174, 827.	5.1	0
83	Prevalence of glucose abnormalities among patients presenting with an acute myocardial infarction. American Heart Journal, 2014, 168, 466-470.e1.	2.7	58
84	Type of Î²-blocker use among patients with versus without diabetes after myocardial infarction. American Heart Journal, 2014, 168, 273-279.e1.	2.7	14
85	HbA1c and Risk of Severe Hypoglycemia in Type 2 Diabetes. Diabetes Care, 2013, 36, 3535-3542.	8.6	202
86	The Reliability and Prognosis of In-Hospital Diagnosis of Metabolic Syndrome in the Setting of Acute Myocardial Infarction. Journal of the American College of Cardiology, 2013, 62, 704-708.	2.8	15
87	Elevated HbA1c and Fasting Plasma Glucose in Predicting Diabetes Incidence Among Older Adults. Diabetes Care, 2013, 36, 3923-3929.	8.6	40
88	Glucose Control in Older Adults With Diabetes Mellitusâ€™More Harm Than Good?. JAMA Internal Medicine, 2013, 173, 1306.	5.1	26
89	Glucose Variability and Mortality in Patients Hospitalized With Acute Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 550-557.	2.2	34
90	Management of blood glucose in patients with acute coronary syndromes. Reviews in Cardiovascular Medicine, 2012, 13, e77-88.	1.4	0

#	ARTICLE	IF	CITATIONS
91	Management of Blood Glucose in Patients With Acute Coronary Syndromes. Reviews in Cardiovascular Medicine, 2012, 13, 77-88.	1.4	0
92	Use of Metformin in the Setting of Mild-to-Moderate Renal Insufficiency. Diabetes Care, 2011, 34, 1431-1437.	8.6	361
93	Switching From Rosiglitazone. JAMA - Journal of the American Medical Association, 2011, 305, 820.	7.4	8
94	Hypoglycemia and adverse outcomes: marker or mediator?. Reviews in Cardiovascular Medicine, 2011, 12, 132-5.	1.4	14
95	Discontinuation of Antihyperglycemic Therapy and Clinical Outcomes After Acute Myocardial Infarction in Older Patients With Diabetes. Circulation: Cardiovascular Quality and Outcomes, 2010, 3, 236-242.	2.2	31
96	Identifying Dysglycemic States in Older Adults: Implications of the Emerging Use of Hemoglobin A1c. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 5289-5295.	3.6	100
97	Cardiovascular risk-benefit ratio of thiazolidinediones. Current Cardiovascular Risk Reports, 2009, 3, 42-50.	2.0	3
98	Considerations for Generic-to-Generic Levothyroxine Switchingâ€”Reply. JAMA Internal Medicine, 0, , .	5.1	0